blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2483266

EP2483266 - COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.01.2016
Database last updated on 17.05.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Cadila Healthcare Limited
Zydus Tower Satellite Cross Roads
Ahmedabad 380 015, Gujarat / IN
[2012/32]
Inventor(s)01 / PINGALI, Harikishore
Cadila Healthcare Limited
Zydus Tower
Satellite Cross Roads
Ahmedabad 380 015
Gujarat / IN
02 / KALAPATAPU, V., V., M., Sairam
Cadila Healthcare Limited
Zydus Tower
Satellite Cross Roads
Ahmedabad 380 015
Gujarat / IN
03 / MAKADIA, Pankaj
Cadila Healthcare Limited
Zydus Tower
Satellite Cross Roads
Ahmedabad 380 015
Gujarat / IN
04 / JAIN, Mukul, R.
Cadila Healthcare Limited
Zydus Tower
Satellite Cross Roads
Ahmedabad 380 015
Gujarat / IN
 [2012/32]
Representative(s)Viering, Jentschura & Partner mbB Patent- und Rechtsanwälte
Hamborner Straße 53
40472 Düsseldorf / DE
[N/P]
Former [2015/09]Viering, Jentschura & Partner Patent- und Rechtsanwälte
Kennedydamm 55 / Roßstrasse
40476 Düsseldorf / DE
Former [2012/32]Viering, Jentschura & Partner
Kennedydamm 55/Roßstr.
40476 Düsseldorf / DE
Application number, filing date10810948.929.09.2010
WO2010IN00650
Priority number, dateIN2009MUM229201.10.2009         Original published format: IN MU22922009
[2012/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011051961
Date:05.05.2011
Language:EN
[2011/18]
Type: A1 Application with search report 
No.:EP2483266
Date:08.08.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application.
[2012/32]
Type: B1 Patent specification 
No.:EP2483266
Date:25.02.2015
Language:EN
[2015/09]
Search report(s)International search report - published on:EP05.05.2011
ClassificationIPC:C07D405/06, C07D405/14, C07D413/06, C07D413/14, C07D417/06, C07D417/14, A61K31/357, A61P3/06
[2012/32]
CPC:
C07D413/06 (EP,US); A61K31/357 (KR); A61P3/06 (EP);
A61P43/00 (EP); C07D405/06 (EP,US); C07D405/14 (KR);
C07D413/14 (EP,KR,US); C07D417/06 (EP,US); C07D417/14 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/32]
Extension statesBA02.05.2012
ME02.05.2012
RS02.05.2012
TitleGerman:VERBINDUNGEN ZUR BEHANDLUNG VON DYSLIPIDÄMIE UND ASSOZIIERTEN ERKRANKUNGEN[2012/32]
English:COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES[2012/32]
French:COMPOSÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE ET DE MALADIES ASSOCIÉES[2012/32]
Entry into regional phase05.04.2012National basic fee paid 
05.04.2012Designation fee(s) paid 
05.04.2012Examination fee paid 
Examination procedure21.04.2011Request for preliminary examination filed
International Preliminary Examining Authority: EP
05.04.2012Examination requested  [2012/32]
07.12.2012Amendment by applicant (claims and/or description)
16.07.2013Despatch of a communication from the examining division (Time limit: M04)
19.09.2013Reply to a communication from the examining division
10.09.2014Communication of intention to grant the patent
08.01.2015Fee for grant paid
08.01.2015Fee for publishing/printing paid
09.01.2015Receipt of the translation of the claim(s)
Divisional application(s)EP12195826.8  / EP2567957
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.07.2013
Opposition(s)26.11.2015No opposition filed within time limit [2016/05]
Fees paidRenewal fee
01.10.2012Renewal fee patent year 03
30.09.2013Renewal fee patent year 04
29.09.2014Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.09.2010
AL25.02.2015
BG25.02.2015
CY25.02.2015
CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
MK25.02.2015
MT25.02.2015
SI25.02.2015
SK25.02.2015
SM25.02.2015
GR26.05.2015
IS25.06.2015
LU29.09.2015
[2018/46]
Former [2018/30]HU29.09.2010
BG25.02.2015
CY25.02.2015
CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
MK25.02.2015
MT25.02.2015
SI25.02.2015
SK25.02.2015
SM25.02.2015
GR26.05.2015
IS25.06.2015
LU29.09.2015
Former [2017/38]HU29.09.2010
BG25.02.2015
CY25.02.2015
CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
MT25.02.2015
SI25.02.2015
SK25.02.2015
SM25.02.2015
GR26.05.2015
IS25.06.2015
LU29.09.2015
Former [2017/22]CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
MT25.02.2015
SI25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
LU29.09.2015
Former [2016/23]CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
SI25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
LU29.09.2015
Former [2016/21]CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
SI25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
LU29.09.2015
Former [2016/12]CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
SI25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/49]CZ25.02.2015
EE25.02.2015
HR25.02.2015
LT25.02.2015
LV25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/39]HR25.02.2015
LT25.02.2015
LV25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/38]HR25.02.2015
LT25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/37]HR25.02.2015
LT25.02.2015
GR26.05.2015
Former [2015/36]HR25.02.2015
LT25.02.2015
Former [2015/35]LT25.02.2015
Cited inInternational search[X]WO2004099173  (THERACARB INC [CA], et al) [X] 1-4 * page 53; example 43; compound 19 *;
 [A]WO2009100297  (MERCK & CO INC [US], et al) [A] 1-15 * abstract * * claims 1-25 * * page 21, paragraph 2 *;
 [XP]US2009275053  (HORTON JAY D [US], et al) [XP] 12,13* the whole document *
by applicant   - PNAS, (2009), vol. 106, pages 9546 - 9547
    - JOURNAL OF BIOLOGICAL CHEMISTRY, (2009), vol. 284, pages 10561 - 10570
    - NATUR'E STRUCTURAL AND MOLECULAR BIOLOGY, (2007), vol. 14, pages 413 - 419
    - NATURE GENETICS, (2003), vol. 34, pages 154 - 156
    - TRENDS IN BIOCHEMICAL SCIENCES, (2008), vol. 33, pages 426 - 434
    - J LIPID RES., (2008), vol. 49, pages 1333 - 1343
    - NATURE STRUCTURAL AND MOLECULAR BIOLOGY, (2007), vol. 14, pages 413 - 419
    - STRUCTURE, (2007), vol. 15, pages 545 - 552
    - DRUG NEWS PERSPECTIVES, (2008), vol. 21, pages 323 - 330
    - BIOCHEMICAL JOURNAL, (2009), vol. 419, pages 577 - 584
    - PNAS, (2008), vol. 105, pages 11915 - 11920
    - JOURNAL OF LIPID RESEARCH, (2007), vol. 48, pages 763 - 767
    - PNAS, (2009), vol. 106, pages 9820 - 9825
    - DRUG NEWS PERSPECT, (200807), vol. 21, no. 6, pages 323 - 330
    - PNAS, (2009), vol. 106, no. 24, pages 9546 - 9547
    - CURR ATHEROSCLER REP, (2010), vol. 12, pages 308 - 315
    - PNAS, (2008), vol. 105, no. 6, pages 1820 - 1825
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.